Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in Chinese cardiac recipients

Circulation Journal

Volumn 71, Issue 6, 2007, Pages 968-972

  Chen, I Ming ^a,b   Chang, Hsiao Huang ^a,b   Hsu, Chiao Po ^a,b   Lai, Shiau Ting ^a,b   Hsieh, Yuan Chen ^a,b   Shih, Chun Che ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cardiac transplant; Cytomegalovirus; Leucopenia; Valganciclovir

Indexed keywords

VALGANCICLOVIR;

ADULT; ARTICLE; BODY MASS; CARDIAC PATIENT; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; RECIPIENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CHINA; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HEART DISEASES; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34249667227     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.968     Document Type: Article

References (14)

1. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001; 3(Suppl 2): 1-5.
2. Bueno J, Ramil C, Green M. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatr Drugs 2002; 4: 279-290.
3. Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171: 1014-1018.
4. Isenberg AL, Shen GK, Singh TP, Hahn A, Conti DJ. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy. Clin Transplant 2000; 14: 193-198.
5. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-2815.
6. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
7. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119-1126.
8. Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: Improvement in clinical outcomes. J Heart Lung Transplant 2005; 24: 1343-1346.
9. Wada K, Takada M, Ueda T, Ochi H, Morishita H, Hanatani A, et al. Pharmacokinetic study and limited sampling strategy of cyclosporine in Japanese heart transplant recipients. Circ J 2006; 70: 1307-1311.
10. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218-227.
11. Fellay J, Venetz JP, Pacual M, Aubert JD, Seudoux C, Meylan PR. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Am J Transplant 2005; 5: 1781-1782.
12. Aigner C, Jaksch P, Winkler G, Czebe K, Taghavi S, Marta G, et al. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation. Wien Klin Wochenschr 2005; 117: 480-484.
13. Taber DJ, Ashcraft E, Baillie GM, Berkman S, Rogers J, Baliga PK, et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004; 6: 101-109.
14. Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79: 1477-1483.